Who Owns The Oncology Institute Company?

Who owns The Oncology Institute of Hope and Innovation?

The Oncology Institute of Hope and Innovation went public in November 2021 via a merger valuing it at $842 million, shifting control from founder clinicians to institutional investors and public shareholders. Its value-based model and leadership stakes remain central to governance.

As of early 2025, TOI runs over 100 clinics across five states; voting control rests with major healthcare-focused institutions and remaining founder leadership, affecting strategy and at-risk contract management. See The Oncology Institute Porter's Five Forces Analysis.

Founded in 2007 by Dr. Richy Agajanian, The Oncology Institute began as a physician-owned private practice with nearly 100 percent equity held by Dr. Agajanian and a small group of clinical partners, enabling reinvestment into clinic growth and clinical trials.

Founder and clinical leadership

Dr. Richy Agajanian, a hematologist-oncologist, led clinical strategy and research initiatives that shaped the company’s early model.

Private practice ownership

From 2007–2017 the ownership was tightly held by founders under a traditional private practice equity structure.

Reinvestment strategy

Profits were reinvested into clinic expansion and a proprietary clinical trial program rather than distributed broadly.

Shift to external capital

In 2018 a healthcare-focused private equity firm acquired a significant minority stake to fund geographic expansion beyond Southern California.

Valuation at investment

The 2018 transaction valued the company in the mid-nine-figure range and introduced formal vesting and buy-sell provisions for founders.

Governance changes

External professional management was added while agreements preserved founder control over clinical vision and operations.

Ownership changes in 2018 marked the transition from near-total founder ownership to a private equity-backed structure, affecting The Oncology Institute ownership, corporate structure, and subsequent leadership team evolution.

Key facts and timeline

Founders retained control through structured agreements while raising growth capital to scale operations.

• Founded: 2007 by Dr. Richy Agajanian
• Ownership pre-2018: nearly 100% founder-held equity
• 2018: minority private equity investment valuing company in the mid-nine figures
• Post-2018: vesting schedules and buy-sell clauses preserved founders’ clinical control

Further context on capital models and revenue strategy is available in this article: Revenue Streams & Business Model of The Oncology Institute

Complete The Oncology Institute Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Key ownership events include the November 15, 2021 SPAC business combination with DFP Healthcare Acquisitions Corp that took The Oncology Institute public, shifting control from private equity and founders to a broad institutional base and setting an initial market cap above $800,000,000.

Ownership evolution from private-equity and founder-dominated stakes to institutional majority ownership reflects market confidence in a value-based oncology platform and underpins a strategy of expansion into lower-penetration 'red-zone' states.

Ownership Dynamics to Watch

Major stakeholders shape strategic moves, capital access and governance; institutional ownership reached about 67.5% by Q1 2025.

• SPAC merger on November 15, 2021 converted the company to public status
• Deerfield’s 35.2% stake is a controlling influence
• Founder ownership remains material at 11.5%
• Institutional mix includes Fidelity and Vanguard driving liquidity and stability

Further context on strategic implications and investor communications is available in the company’s investor materials and in this analysis of corporate positioning: Marketing Strategy of The Oncology Institute

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

The Oncology Institute board comprises nine directors balancing investor representation and clinical leadership; the single-class 'one-share-one-vote' structure ties voting power to economic ownership and limits founder-entrenched control typical of dual-class firms.

The board composition meets NASDAQ independent director requirements and aligns the Oncology Institute ownership structure with investor oversight while preserving clinical input.

Voting power and control dynamics

The Oncology Institute operates a single-class share structure where each common share equals one vote; Deerfield Management's concentrated stake results in significant de facto influence over strategic actions.

• One-share-one-vote structure ties voting to economic interest
• Board of nine directors includes CEO, founder, institutional reps, and four independent directors
• Deerfield Management holds the largest block, effectively controlling major corporate decisions
• No high-profile proxy fights reported through early 2025

For context on culture and governance principles, see Mission, Vision & Core Values of The Oncology Institute.

The Oncology Institute Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Over the past three years TOI’s ownership shifted toward concentrated stakes held by long-term institutional believers while early private equity backers gradually diluted; active value-based care investors increased as passive index holdings fell during the 2023 market downturn.

Recent SEC filings and 2024–2025 disclosures show no significant repurchase program and emphasize capital efficiency, clinical footprint growth and measured founder liquidity events; stakeholders are adopting a wait-and-see stance as TOI manages medical loss ratios in new markets.

Ownership concentration

Active institutional investors specializing in value-based care replaced much passive index ownership after 2023, increasing governance engagement.

Capital allocation

Management prioritized cash for expansion over buybacks, enabling growth to 110 locations by early 2025 and preserving runway.

M&A prospects

Analysts view TOI as a plausible target for privatization or strategic acquisition as it approaches EBITDA positivity and consolidates market share.

Governance signals

Founders remain top holders despite partial sales; increased active ownership suggests closer oversight of medical loss ratios and network economics.

For deeper context on strategy and ownership evolution see Growth Strategy of The Oncology Institute

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE